Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease

Neurosci Lett. 2003 May 8;341(3):201-4. doi: 10.1016/s0304-3940(03)00185-x.


Features of Parkinson's disease (PD) include oxidative stress, nigral mitochondrial complex I deficiency and visual dysfunction, all of which are also associated with coenzyme Q(10) (CoQ(10)) deficiency. The objective of this monocenter, parallel group, placebo controlled, double-blind trial was to determine the symptomatic response of daily oral application of 360 mg CoQ(10) lasting 4 weeks on scored PD symptoms and visual function, measured with the Farnsworth-Munsell 100 Hue test (FMT), in 28 treated and stable PD patients. CoQ(10) supplementation provided a significant (P=0.01) mild symptomatic benefit on PD symptoms and a significantly (F((1,24))=8.48, P=0.008) better improvement of FMT performance compared with placebo. Our results indicate a moderate beneficial effect of oral CoQ(10) supplementation in PD patients.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Analysis of Variance
  • Coenzymes
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Parkinson Disease / psychology
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / therapeutic use*


  • Coenzymes
  • Ubiquinone
  • coenzyme Q10